GSK plc (GSK)
NYSE: GSK · Real-Time Price · USD
40.30
-0.06 (-0.15%)
At close: Sep 18, 2025, 4:00 PM EDT
40.30
0.00 (0.00%)
After-hours: Sep 18, 2025, 7:00 PM EDT
GSK Revenue
GSK had revenue of 7.99B GBP in the quarter ending June 30, 2025, with 1.29% growth. This brings the company's revenue in the last twelve months to 31.63B, up 0.59% year-over-year. In the year 2024, GSK had annual revenue of 31.38B with 3.46% growth.
Revenue (ttm)
31.63B GBP
Revenue Growth
+0.59%
P/S Ratio
1.85
Revenue / Employee
460,898 GBP
Employees
68,629
Market Cap
80.37B USD
Revenue Chart
* This company reports financials in GBP.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 31.38B | 1.05B | 3.46% |
Dec 31, 2023 | 30.33B | 1.00B | 3.42% |
Dec 31, 2022 | 29.32B | 4.63B | 18.74% |
Dec 31, 2021 | 24.70B | 342.00M | 1.40% |
Dec 31, 2020 | 24.35B | -9.40B | -27.85% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
GSK News
- 1 day ago - UK's GSK announces $30 billion U.S. pharma investment amid Trump state visit - CNBC
- 1 day ago - GSK and Eli Lilly are the latest multinational drugmakers to unveil plans to build more U.S. manufacturing plants and other operations, moves aimed partly at mitigating the threat of tariffs - WSJ
- 2 days ago - GSK plans $30 billion US investment as pharma tariff threat looms - Reuters
- 2 days ago - GSK Says It Will Spend $30B on U.S. Manufacturing and R&D - Barrons
- 3 days ago - Dividend Income Summary: Lanny's July 2025 Summary - Seeking Alpha
- 8 days ago - US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says - Reuters
- 15 days ago - Why Is GSK Partner Wave Life Sciences Stock Trading Lower On Wednesday? - Benzinga
- 4 weeks ago - Dynavax's shingles vaccine shows similar immune response to GSK's shot in study - Reuters